ElectRx

ElectRx is a pre-clinical stage bioelectronic medicine company focused on developing minimally invasive neuromodulation therapies for chronic inflammatory and autoimmune diseases. The company utilizes a proprietary closed-loop platform designed to sense neural activity and deliver precise electrical stimulation to the peripheral nervous system, specifically targeting the inflammatory reflex. By modulating these neural pathways, ElectRx aims to provide a localized and programmable alternative to systemic immunosuppressive drugs, which often carry significant side effects. Its lead programs are currently in the pre-clinical phase, focusing on high-burden indications such as rheumatoid arthritis and inflammatory bowel disease. The company was established through a company creation initiative by 4BIO Capital and represents a growing field of "electroceuticals" that bridge the gap between medical devices and traditional pharmacology.